Radium drinks and the Radithor tragedy

The order came before the death

Radithor’s danger was that it really contained the radioactive ingredient its maker advertised. William J. Bailey sold radium water as a health remedy through Bailey Radium Laboratories in East Orange, New Jersey.^[1] Industrialist Eben Byers became its best-known victim after prolonged use and death in 1932. But the Federal Trade Commission’s order against the company came on 19 December 1931, before he died.^[2] The dates separate three different developments: an individual’s poisoning, action against misleading sales claims, and later changes to federal drug law.

The bottle and Byers’s exposure

ORAU’s museum preserves a Radithor bottle and describes Bailey’s guarantee that the water contained radium-226 and radium-228.^[1] That guarantee concerned an ingredient, not a demonstrated medical benefit. McGill’s Office for Science and Society describes advertising that promised improvements in metabolism and nutrition and the removal of waste from the body.^[3] These were the seller’s claims. Confirming radioactivity in a bottle could not establish that repeated consumption improved health or was harmless. A measurable ingredient supplied the appearance of scientific precision while leaving the important questions unanswered.

The museum history places Byers’s arm injury in 1927 and his use of Radithor from December that year, following a physician’s recommendation.^[1] It describes early enthusiasm followed by deteriorating health; he stopped taking it in 1930.^[1] During the FTC investigation, Robert Winn visited him and described extensive damage, including the surgical removal of much of his jaw. Byers died in 1932, and his case received national attention. This account does not need a precise bottle total. Published totals and intake estimates do not establish an exact personal radiation dose, and repeating one as a settled measurement would give the story more precision than the evidence warrants.

Internal exposure and delayed harm

Swallowing radium placed radioactive material inside the body. Some passes through without being absorbed; some can enter the bloodstream and reach the skeleton.^[5] Radium’s chemical resemblance to calcium helps explain its affinity for bone.^[5] Retained material continues to decay and irradiate surrounding tissue. The ATSDR toxicological profile discusses both skeletal deposition and harmful effects that can emerge after prolonged exposure. This is a general explanation of internal exposure, not a reconstruction of Byers’s dose. It also does not justify changing a documented poisoning and skeletal injury into a specific cancer diagnosis without case-specific evidence.

Radium-226’s physical half-life is about 1,600 years, as listed by the EPA.^[6] It describes the isotope’s rate of radioactive decay. It is not the time that every swallowed amount remains in a person: absorption, excretion and retention are separate biological processes. The other isotope named in the product guarantee, radium-228, has a different physical half-life. Treating all ‘radium’ as one timer obscures those distinctions. A brief initial feeling of improvement could not establish safety from delayed harm.

Retained radium creates an exposure that can continue after consumption stops. That separates immediate experience from eventual harm: feeling better after a dose is not a test for delayed skeletal injury. Byers’s reported early enthusiasm and later deterioration illustrate why testimonials are a particularly weak way to evaluate a product with effects that develop over time.

What the FTC actually ordered

The FTC’s own 1932 annual report supplies a more precise account of the intervention than the familiar claim that Radithor was simply banned after Byers died. Its entry for Bailey Radium Laboratories, docket 1756, records a consent order dated 19 December 1931.^[2] The order required the company to stop misleading representations about safety and therapeutic value, and restricted the use of physicians’ statements that did not concern Radithor itself or were not based on clinical experience with it.^[2] It also addressed misleading authorship of promotional material and the representation that the product was manufactured in the company’s own laboratory. Scientific credentials, testimonials and the company name were part of the sales machinery under scrutiny.

That was an order against specified practices by specified respondents. It should not be expanded into a claim that every radioactive remedy became illegal that day. Nor was it issued in response to a death that had not yet occurred. Byers’s subsequent death made the danger more widely visible; the museum history also records continued medical support for radium water. Enforcement against a seller, publicity about a victim and abandonment of a belief were separate processes.

Separate changes to drug law

Federal drug oversight changed through a longer legislative history. FDA’s chronology explains that the 1906 law addressed adulteration and misbranding, while a 1912 amendment made fraudulent therapeutic labeling actionable under a difficult intent standard.^[4] A comprehensive revision was proposed in 1933. The 1937 Elixir Sulfanilamide disaster added urgency to the pending law, and the 1938 Food, Drug, and Cosmetic Act required new drugs to be shown safe before marketing. That is a different milestone from the Radithor order. The requirement to demonstrate effectiveness before marketing came with the 1962 drug amendments. Attributing this entire sequence to Byers’s death would erase both the earlier enforcement and the later reforms’ distinct purposes.

Read the sources according to the question they answer. The ORAU museum connects the surviving product to Bailey and Byers, drawing on historical research and reproducing an investigator’s description. The contemporary FTC report establishes what the government ordered and when. FDA’s timeline explains the separate legal milestones. ATSDR and EPA explain radiation and internal exposure; they do not provide a newly calculated dose for Byers. The illustrated film follows the same sequence. Radithor shows why proof that a product contains an impressive ingredient cannot stand in for evidence about what that ingredient does to the person taking it.